Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLDX with… →

CLDX Key Statistics

As of Sep 4, 2026

Trading

Open: $38.96
Previous Close: $39.37
Day's Range: 38.90–39.81
52-Week Range: 22.10–45.14
Volume: 414.50K
Beta: 0.84

Valuation

Market Cap: $3.12B
P/E Ratio: unprofitable
EPS (ttm): −4.35

Financials (FY)

Revenue (FY): $1.55M−77.99%
Net Income (FY): −$258.76M
Profit margin: 0.00%
Shares Outstanding: 78.53M
1-Year Return: +74.19%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 1.01M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−92.96%+685.65%+46.10%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+46.10%
2025	+7.48%
2024	−36.28%
2023	−11.02%
2022	+15.35%
2021	+120.55%
2020	+685.65%
2019	−25.67%
2018	−92.96%
2017	−19.77%
2016 (partial year)	−21.68%

As of September 4, 2026.

CLDX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$1.55M	−$258.76M	−16748.0%
2024	$7.02M	−$157.86M	−2248.8%
2023	$6.88M	−$141.43M	−2054.8%
2022	$2.36M	−$112.33M	−4765.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$1.55M	—	−$287.37M	−$258.76M	−16748.0%
2024	$7.02M	—	−$195.08M	−$157.86M	−2248.8%
2023	$6.88M	—	−$142.04M	−$141.43M	−2054.8%
2022	$2.36M	—	−$107.10M	−$112.33M	−4765.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLDX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CLDX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Celldex Therapeutics, Inc. (CLDX) is capitalised at $3.12B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 198.

The 52-week range on file runs from $22.10 to $45.14. CLDX last closed at $39.68 on September 4, 2026. That is +$0.31 (+0.79%) against the previous close. The latest close sits 79.55% above that 52-week low.

Financial Health

In fiscal 2025, Celldex Therapeutics, Inc. reported revenue of $1.55M. That is −77.99% against the prior fiscal year, when revenue was $7.02M. The same year closed with a net loss of $258.76M. Profit margin runs at 0%. Trailing earnings per share are −4.35.

Across the 4 fiscal years on file, revenue moves from $2.36M in 2022 to $1.55M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +74.19%. Across 10 years the annualized return works out at −2.33%. The reported beta is 0.84. Daily returns over the trailing 10 years annualize to a volatility of 77.92%.

Growth & Income

The record shows no dividend for CLDX.

So far in 2026 the price is +46.10%. Across the complete calendar years on file, 2020 returned +685.65% and 2018 returned −92.96%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Celldex Therapeutics, Inc. (CLDX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Celldex Therapeutics, Inc.	CLDX	$3.12B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Celldex Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Visit website →

Celldex Therapeutics, Inc. (CLDX) Stock Analysis